References:
1. Pui CH, Campana D, Pei D, Bowman WP, Sandlund JT, Kaste SC, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med. 2009;360:2730–41.
2. Veerman AJ, Kamps WA, van den Berg H, van den Berg E, Bökkerink JP, Bruin MC, et al. Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997–2004). Lancet Oncol. 2009;10:957–66.
3. Kamps WA, van der Pal-de Bruin KM, Veerman AJP, Fiocco M, Bierings M, Pieters R. Long-term results of Dutch Childhood Oncology Group studies for children with acute lymphoblastic leukemia from 1984 to 2004. Leukemia. 2010;24:309–19.
4. Conter V, Bartram CR, Valsecchi MG, Schrauder A, Panzer-Grümayer R, Möricke A, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood. 2010;115:3206–14.
5. Lehrnbecher T, Koehl U, Wittekindt B, Bochennek K, Tramsen L, Klingebiel T, et al. Changes in host defence induced by malignancies and antineoplastic treatment: implication for immunotherapeutic strategies. Lancet Oncol. 2008;9:269–78.
6. Abdelmabood S, Fouda AE, Boujettif F, Mansour A. Treatment outcomes of children with acute lymphoblastic leukemia in a middle-income developing country: high mortalities, early relapses, and poor survival. J Pediatr (Rio J). 2018;pii: S0021-7557(18)30583-7.
7. van Tilburg CM, Sanders EAM, Nibbelke EE, Pieters R, Revesz T, Westers P, et al. Impact of reduced chemotherapy treatment for good risk childhood acute lymphoblastic leukaemia on infectious morbidity. Br J Haematol. 2011;152:433–40.
8. van Tilburg CM, Bierings MB, Berbers GAM, Wolfs TFW, Pieters R, Bloem AC, et al. Impact of treatment reduction for childhood acute lymphoblastic leukemia on serum immunoglobulins and antibodies against vaccine-preventable diseases. Pediatr Blood Cancer. 2012;58:701–7.
9. Holmes EA, Friedman DL, Connelly JA, Dulek DE, Zhao Z, Esbenshade AJ. Impact of IgG monitoring and IVIG supplementation on the frequency of febrile illnesses in pediatric acute lymphoblastic leukemia patients undergoing maintenance chemotherapy. J PediatrHematolOncol. 2019;41:423–8.
10. Kostaridou S, Polychronopoulou S, Psarra K, Kapsimali V, Kapsimali b V, Katevas P, et al. Decrease of CD4 + and B-lymphocyte populations is not associated with severe infectious complications in children with acute lymphoblastic leukemia during maintenance. Int J Hematol. 2004;80:354–60.
11. Rapson NT, Cornbleet MA, Chessells JM, Bennett AJ, Hardisty RM. Immunosuppression and serious infections in children with acute lymphoblastic leukaemia: A comparison of three chemotherapy regimes. Br J Haematol. 1980;45:41–52.
12. Luczyński W, Stasiak-Barmuta A, Krawczuk-Rybak M, Zak J. Immunologic monitoring in children with acute lymphoblastic leukemia during maintenance treatment with regard to co-existing infections. WiadLek. 2004;57:337–42.
13. Raanani P, Gafter-Gvili A, Paul M, Ben-Bassat I, Leibovici L, Shpilberg O. Immunoglobulin prophylaxis in hematopoietic stem cell transplantation: systematic review and meta-analysis. J ClinOncol. 2009;27:770–81.
14. Narula G, Khodaiji S, Bableshwar A, Bindra MS. Age-related reference intervals for immunoglobulin levels and lymphocyte subsets in Indian children. Indian J PatholMicrobiol. 2017;60:360–4.
15. Meites S, Buffone GJ, editors. Pediatric clinical chemistry : reference (normal) values. 3rd ed. Washington, DC: American Association for Clinical Chemistry; 1989.
16. O’Connor D, Bate J, Wade R, Clack R, Dhir S, Hough R, et al. Infection-related mortality in children with acute lymphoblastic leukemia: an analysis of infectious deaths on UKALL2003. Blood. 2014;124:1056–61.
17. Luczynski W, Stasiak-Barmuta A, Krawczuk-Rybak M. Immunologic monitoring of maintenance therapy for acute lymphoblastic leukaemia in children - preliminary report. Pediatr Blood Cancer. 2004;42:416–20.
18. El-Chennawi FA, Al-Tonbary YA, Mossad YM, Ahmed MA. Immune reconstitution during maintenance therapy in children with acute lymphoblastic leukemia, relation to co-existing infection. Hematology. 2008;13:203–9.
19. Eyrich M, Wiegering V, Lim A, Schrauder A, Winkler B, Schlegel PG. Immune function in children under chemotherapy for standard risk acute lymphoblastic leukaemia - a prospective study of 20 paediatric patients. Br J Haematol. 2009;147:360–70.
20. Lovat PE, Robinson JH, Windebank KP, Kernahan J, Watson JG. Serial study of t lymphocytes in childhood leukemia during remission. PediatrHematolOncol. 1993;10:129–39.
21. Ek T, Mellander L, Hahn-Zoric M, Abrahamsson J. Intensive treatment for childhood acute lymphoblastic leukemia reduces immune responses to diphtheria, tetanus, and Haemophilusinfluenzae type b. J PediatrHematolOncol. 2004;26:727–34.
22. Borzy MS, Ridgway D. Prolonged defects of interleukin-2 production, responsiveness, and receptor expression in patients with acute lymphoblastic leukemia. Blood. 1989;73:1608–14.
23. Boldt DH, Von Hoff DD, Kuhn JG, Hersh M. Effects on human peripheral lymphocytes of in vivo administration of 9-beta-D-arabinofuranosyl-2-fluoroadenine-5’-monophosphate (NSC 312887), a new purine antimetabolite. Cancer Res. 1984;44:4661–6.
24. Haynes BF, Fauci AS. The differential effect of in vivo hydrocortisone on the kinetics of subpopulations of human peripheral blood thymus-derived lymphocytes. J Clin Invest. 1978;61:703–7.
25. Inaba H, Pei D, Wolf J, Howard SC, Hayden RT, Go M, et al. Infection-related complications during treatment for childhood acute lymphoblastic leukemia. Ann Oncol. 2017;28:386–92.